Results 71 to 80 of about 46,198 (239)

Oral Lesions Associated With Hydroxyurea Treatment

open access: yes, 2015
Hydroxyurea (HU) is an antimetabolic agent commonly used in myeloproliferative disorders and hematological diseases as well as in severe psoriasis. Despite of usually be well tolerated, sometimes it can induce immunosuppression and mucocutaneous adverse ...
Mendonça, Regina   +9 more
core   +1 more source

Diagnosis and Management of Prenatal Hereditary Pyropoikilocytosis

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Hereditary pyropoikilocytosis (HPP) is a severe hemolytic anemia caused by variants in SPTA1, SPTB, and EPB41. These weaken horizontal interactions in the erythrocyte cytoskeleton, causing membrane fragmentation and splenic sequestration. It will readily cause fetal anemia and often hydrops fetalis. Prenatal diagnosis requires first ruling out
Connor Hartzell   +6 more
wiley   +1 more source

Topical Hydroxyurea and Psoriasis

open access: yesJournal of Investigative Dermatology, 1972
Hydroxyurea, as a 10% cream, produces a significant involutionary effect on psoriatic plaques when used under continuous plastic film occlusion. When used with only partial occlusion, however, the effect is only slightly better than that of the base alone.
Zackheim, Herschel S.   +2 more
openaire   +2 more sources

Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients

open access: yesBrazilian Journal of Medical and Biological Research, 2003
Hydroxyurea is used for sickle-cell disease patients in order to increase fetal hemoglobin synthesis and consequently decrease the severity of pain episodes.
S.M. Teixeira   +2 more
doaj   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde   +4 more
wiley   +1 more source

Mutagenic and genotoxic effect of hydroxyurea

open access: yes, 2011
The hydroxyurea, a cytotoxic drug, is the mainly available therapeutical strategy for the treatment of sickle cell disease. This study aimed to evaluate the mutagenic and genotoxic potential of the hydroxyurea through the Salmonella/Microsome assay and ...
Almeida, Adelia Emilia de   +4 more
core   +3 more sources

Catalase-Mediated Nitric Oxide Formation from Hydroxyurea

open access: yes, 2016
Hydroxyurea reduces the incidence of painful crises in patients with sickle cell disease and has recently been approved for the treatment of this condition.
Jinming Huang (390392)   +2 more
core   +1 more source

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia

open access: yesTrials, 2020
Background Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide.
Emily R. Meier   +18 more
doaj   +1 more source

Sickle Cell Disease: Historical Overview and Current Therapies

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide, yet the limited treatment options currently available do not always adequately control the disease and carry significant side effects. At present, the only curative treatment is hematopoietic stem cell (HSC) transplantation, a procedure that carries considerable challenges and numerous ...
Oluwaseun O. Babatunde   +4 more
wiley   +1 more source

The Association Between Hydroxyurea Treatment and Pain Intensity, Analgesic Use, and Utilization in Ambulatory Sickle Cell Anemia Patients. [PDF]

open access: yes, 2011
Background.  We compared daily pain, home analgesic use, and utilization among ambulatory adults in the randomized Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH).
Ballas, Samir K   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy